You are on page 1of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 1 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 2 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 3 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 4 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 5 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 6 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 7 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 8 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 9 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 10 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 11 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 12 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 13 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 14 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 15 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 16 of 35

use in infant formula.

ECF No. 78-1 at 31.

It contends this

interpretation excludes resellers, companies that make their own DHA and ARA but do not sell to others, and product given away for testing purposes from the relevant product market. Id. at 32.

Despite Marteks argument, under the interchangeability test there is no reason for the market to exclude resellers of DHA and ARA. There is no

evidence that DHA and ARA that has been resold differ from BNLfoods DHA and ARA--nor does Martek argue such. Despite arguably unclear pleading by

BNLfood, under the interchangeability rule, a reasonable jury could find that resellers are included in BNLfoods definition. at 404; Def. Ex. 2 at 134:6-20. See DuPont, 351 U.S.

Similarly, manufacturers of infant

formula who make their own DHA and ARA or distribute the phospholipids without change can be found to be included in the market. See Berlyn, 73

F. Appx at 852-53 (adjusting analysis of market to the relevant consumer when improperly pled and argued). Marteks argument about BNLfoods

description of the alleged market is too restrictive--its focus should be on the realities and operations of that market. See id. Martek has not

shown any fatal deficiencies in BNLfoods definition of

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 17 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 18 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 19 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 20 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 21 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 22 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 23 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 24 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 25 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 26 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 27 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 28 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 29 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 30 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 31 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 32 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 33 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 34 of 35

Case 1:11-cv-00446-WDQ Document 92 Filed 03/28/13 Page 35 of 35

You might also like